Ipsen Positive On Palovarotene Despite Troubled Past
Filings For FOP In Early 2021
Despite concerns over toxicity due to early growth plate closure in skeletally immature patients, Ipsen's CEO David Loew is confident that palovarotene will get through regulatory review for fibrodysplasia ossificans progressive.
